KR20230039718A - 보체 인자 c3의 억제제 및 이들의 의학적 용도 - Google Patents

보체 인자 c3의 억제제 및 이들의 의학적 용도 Download PDF

Info

Publication number
KR20230039718A
KR20230039718A KR1020237005557A KR20237005557A KR20230039718A KR 20230039718 A KR20230039718 A KR 20230039718A KR 1020237005557 A KR1020237005557 A KR 1020237005557A KR 20237005557 A KR20237005557 A KR 20237005557A KR 20230039718 A KR20230039718 A KR 20230039718A
Authority
KR
South Korea
Prior art keywords
compstatin analog
pharmaceutically acceptable
compstatin
disease
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005557A
Other languages
English (en)
Korean (ko)
Inventor
안네 페르닐레 토프텡 쉘톤
헨드릭 피셔 뭉크
라스무스 레트
Original Assignee
제트피 에스피브이 3 케이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제트피 에스피브이 3 케이/에스 filed Critical 제트피 에스피브이 3 케이/에스
Publication of KR20230039718A publication Critical patent/KR20230039718A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
KR1020237005557A 2020-07-16 2021-07-15 보체 인자 c3의 억제제 및 이들의 의학적 용도 Pending KR20230039718A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20186297 2020-07-16
EP20186297.6 2020-07-16
PCT/EP2021/069798 WO2022013374A1 (en) 2020-07-16 2021-07-15 Inhibitors of complement factor c3 and their medical uses

Publications (1)

Publication Number Publication Date
KR20230039718A true KR20230039718A (ko) 2023-03-21

Family

ID=71661768

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005557A Pending KR20230039718A (ko) 2020-07-16 2021-07-15 보체 인자 c3의 억제제 및 이들의 의학적 용도

Country Status (11)

Country Link
US (1) US20230287051A1 (https=)
EP (1) EP4182023A1 (https=)
JP (1) JP2023538807A (https=)
KR (1) KR20230039718A (https=)
CN (1) CN116209671A (https=)
AU (1) AU2021309548A1 (https=)
CA (1) CA3185730A1 (https=)
CO (1) CO2023001411A2 (https=)
IL (1) IL299870A (https=)
MX (1) MX2023000679A (https=)
WO (1) WO2022013374A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020128624A (ru) 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN120359233A (zh) * 2022-11-24 2025-07-22 阿麦达斯制药美国有限责任公司 用于基于载体的疗法的坎普他汀类似物
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物
CN119219741A (zh) * 2023-06-29 2024-12-31 刘晓蓉 新型补体抑制剂及其制备、应用和产品

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
PT1549333E (pt) 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
EP2662089A3 (en) 2005-10-08 2014-02-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
CN102977191B (zh) 2005-11-28 2016-08-10 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
RU2606120C2 (ru) * 2011-08-31 2017-01-10 Хантсман Эдванст Матириалз (Свитзеленд) Гмбх Способ пропитки реакторов с воздушным сердечником, подвергнутый пропитке реактор с воздушным сердечником и применение системы пропитки
CA2847862C (en) 2011-09-07 2021-01-12 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
US10213476B2 (en) * 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
RU2020128624A (ru) * 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
BR112022003760A2 (pt) * 2019-08-27 2022-05-31 Zp Spv 3 K/S Análogos de compstatina e seus usos médicos

Also Published As

Publication number Publication date
EP4182023A1 (en) 2023-05-24
MX2023000679A (es) 2023-04-18
CA3185730A1 (en) 2022-01-20
AU2021309548A1 (en) 2023-02-23
CO2023001411A2 (es) 2023-02-16
IL299870A (en) 2023-03-01
WO2022013374A1 (en) 2022-01-20
US20230287051A1 (en) 2023-09-14
JP2023538807A (ja) 2023-09-12
CN116209671A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
US12600749B2 (en) Compstatin analogues and their medical uses
KR20230039718A (ko) 보체 인자 c3의 억제제 및 이들의 의학적 용도
AU2018210174B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7711044B2 (ja) コンプスタチン類似体及びその医学的使用
JP2020128443A (ja) インターロイキン２３受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用
BR112016008996B1 (pt) Ligante peptídico específico para calicreína plasmática e composição farmacêutica
US10421785B2 (en) Delta receptor agonist peptides and use thereof
EA051613B1 (ru) Ингибиторы фактора с3 системы комплемента и варианты их применения в медицине
HK40092906A (zh) 补体因子c3的抑制剂及其医学用途
EA049126B1 (ru) Аналоги компстатина и пути их медицинского применения
HK40102364A (en) Compstatin analogues and their medical uses
HK40102364B (en) Compstatin analogues and their medical uses
US20210238229A1 (en) Peptide for disease treatment
KR20250166123A (ko) 신경계 복구를 위한 단백질 티로신 포스파타제 웨지 도메인 펩티드 이량체

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902